TARS — Tarsus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.47bn
- $3.09bn
- $451.36m
Tarsus hits over one-month high on strong demand for eye drop
Brief: Tarsus Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: Tarsus Pharmaceuticals Q3 Operating Expenses USD 42.806 Million
Brief: Tarsus To Ring Nasdaq Stock Market Closing Bell In Celebration Of The Launch Of Xdemvy
Tarsus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Tarsus Pharmaceuticals Q2 EPS USD -1.17
Tarsus Pharmaceuticals Inc expected to post a loss of $1.08 a share - Earnings Preview
Tarsus tumbles on $100 mln equity raise to fund eye drug launch
Brief: Tarsus Pharmaceuticals Says Public Offering Of 5.71 Mln Common Shares Priced At $17.50 Per Share
Tarsus drops on concerns over newly approved eye disease drug
Brief: FDA Approves XDEMVY™ (Lotilaner Ophthalmic Solution) 0.25% For The Treatment Of Demodex Blepharitis
Brief: Tarsus Pharmaceuticals posts Q1 EPS USD -0.88
Tarsus Pharmaceuticals Inc expected to post a loss of 94 cents a share - Earnings Preview
Brief: Tarsus Appoints Jeff Farrow As Chief Financial Officer And Chief Strategy Officer
Tarsus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Tarsus Reports Full-Year 2022 Financial Results And Recent Business Achievements
Tarsus Pharmaceuticals Inc expected to post a loss of 69 cents a share - Earnings Preview
Brief: Tarsus Added To Nasdaq Biotechnology Index
Brief: Tarsus Announces Positive Topline Data From Phase 1B Trial Evaluating TP-05 For The Prevention Of Lyme Disease